We had a witness in the previous panel who suggested that the results of these changes to the PMPRB would be like Tesla getting $100,000 for its vehicle in the United States but in Canada only getting $50,000 for the same vehicle, so why is anyone going to want to sell in Canada?
We've also heard, I think on this panel, too, people talking about reductions in profits. These will result in a reduction in their asking price from 90% to 92%.
Professor McCabe, with those particular examples, is this legislation that draconian that it's going to cause such a loss of profits for a pharmaceutical company?